NATCO Pharma Limited (NSE:NATCOPHARM)
885.00
+0.30 (0.03%)
Feb 18, 2026, 12:10 PM IST
NATCO Pharma Revenue
NATCO Pharma had revenue of 6.47B INR in the quarter ending December 31, 2025, with 36.33% growth. This brings the company's revenue in the last twelve months to 45.63B, up 6.60% year-over-year. In the fiscal year ending March 31, 2025, NATCO Pharma had annual revenue of 44.32B with 10.74% growth.
Revenue (ttm)
45.63B
Revenue Growth
+6.60%
P/S Ratio
3.47
Revenue / Employee
10.87M
Employees
4,199
Market Cap
158.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 44.32B | 4.30B | 10.74% |
| Mar 31, 2024 | 40.02B | 12.94B | 47.76% |
| Mar 31, 2023 | 27.09B | 7.62B | 39.17% |
| Mar 31, 2022 | 19.46B | -1.10B | -5.35% |
| Mar 31, 2021 | 20.56B | 1.41B | 7.37% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Piramal Pharma | 88.71B |
| Emcure Pharmaceuticals | 88.50B |
| Alembic Pharmaceuticals | 72.67B |
| Gland Pharma | 61.13B |
| Ajanta Pharma | 52.02B |
| Strides Pharma Science | 47.26B |
| Akums Drugs and Pharmaceuticals | 42.60B |
| Wockhardt | 31.93B |
NATCO Pharma News
- 2 days ago - Why are NATCO Pharma shares up over 9% today: Explained - Business Upturn
- 4 days ago - NATCO Pharma gets CDSCO approval for Generic Semaglutide Injection, launch set for March 2026 - Business Upturn
- 4 days ago - Natco Pharma Ltd (BOM:524816) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and ... - GuruFocus
- 4 days ago - Q3 2026 Natco Pharma Ltd Earnings Call Transcript - GuruFocus
- 5 days ago - Natco Pharma receives USFDA EIR for Chennai API unit; Inspection classified as VAI - Business Upturn
- 5 days ago - Natco Pharma Q3 Results: Revenue jumps 36.3% YoY to Rs 647.3 crore, net profit up 14.3% - Business Upturn
- 19 days ago - Pharma sector stocks today, Jan 30: Aurobindo Pharma jumps 3%, Ajanta Pharma up 2%, Natco Pharma rises 2% - Business Upturn
- 22 days ago - Pharma sector stocks today, Jan 27: Syngene down 7%, Natco Pharma falls 2.31%, Alembic Pharma down 1% - Business Upturn